Patents Examined by M Franco G Salvoza
  • Patent number: 10005833
    Abstract: The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: June 26, 2018
    Assignees: WASHINGTON STATE UNIVERSITY, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Santanu Bose, Philippe Tessier
  • Patent number: 9987350
    Abstract: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human Enterovirus B, Human enterovirus C, Human Enterovirus D antigens and their use in vaccines for the prevention of an enterovirus infection.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: June 5, 2018
    Assignee: SENTINEXT THERAPEUTICS Sdn Bhd
    Inventors: Mary Jane Cardosa, Mohamad Fakruddin Jamiluddin, Sharifah Binti Hamid
  • Patent number: 9975923
    Abstract: The present invention provides methods and compositions comprising a chimeric norovirus capsid protein comprising a norovirus VP1 major capsid protein backbone comprising a norovirus epitope selected from the group consisting of: a) Epitope A; b) Epitope B; c) Epitope C; d) Epitope D; e) Epitope E; f) Epitope F; and g) any combination of (a) through (f) above, wherein the norovirus epitope is from a norovirus strain that is different from the norovirus VP1 major capsid protein backbone.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 22, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Ralph Steven Baric, Lisa Chon Lindesmith, Kari Moore Debbink, Eric Francis Donaldson, Jesica Anne Swanstrom
  • Patent number: 9969985
    Abstract: The present disclosure relates generally to the field of viral vaccines. Particularly, the present disclosure provides a modified Vero-adapted human rotavirus strain and a culturing method to produce high titer virus, a rotavirus vaccine, vaccination protocols and diagnostic and prognostic assays.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: May 15, 2018
    Assignee: Murdoch Childrens Research Institute
    Inventors: Carl Kirkwood, Ruth Frances Bishop, Graeme Laurence Barnes
  • Patent number: 9943592
    Abstract: Pharmaceutical or veterinary compositions, vaccine systems, methods, and kits for treating or protecting a subject from a condition using peptide-based adjuvants are provided. The peptide adjuvants comprise a peptide having a hydrophobic region, a turning region, and a hydrophilic region. The turning region comprises amino acid residues GSII (SEQ ID NO: 10). The peptide adjuvants can be used to immunopotentiate active agents by improving the immune response to the active agent.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: April 17, 2018
    Assignee: KANSAS STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Xiuzhi Susan Sun, Jishu Shi
  • Patent number: 9938541
    Abstract: The invention provides an AAV particle containing an adeno-associated viral (AAV) capsid protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30 of the sequence listing; a nucleic acid that encodes this capsid protein; DNA containing this nucleic acid; a cell containing this DNA; and a method for producing this cell.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 10, 2018
    Assignee: TAKARA BIO INC.
    Inventors: Toshikazu Nishie, Fuyuko Takashima, Tatsuji Enoki, Junichi Mineno
  • Patent number: 9938559
    Abstract: A bismuth-containing concentration agent for microorganisms is provided. Additionally, articles that include the concentration agent and methods of concentrating a microorganism using the concentration agent are provided.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: April 10, 2018
    Assignee: 3M Innovative Properties Company
    Inventors: Manjiri T. Kshirsagar, Evan Koon Lun Yuuji Hajime, Andrew W. Rabins
  • Patent number: 9845358
    Abstract: This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 19, 2017
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Andrew Pincetic